BioNTech SE (BNTX) Other Non-Current Liabilities (2018 - 2025)

BioNTech SE has disclosed Other Non-Current Liabilities across 8 years of filings, most recently posting $169.1 million for Q4 2025.

• Other Non-Current Liabilities for Q4 2025 came in at $169.1 million, up 9.31% year-over-year; the trailing twelve-month figure through Dec 2025 was $169.1 million (up 9.31% YoY), and the FY2025 annual result was $164.2 million, up 6.09% from the prior year.
• Other Non-Current Liabilities came in at $169.1 million for Q4 2025 at BioNTech SE, down from $247.3 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $803.3 million in Q3 2024 to a low of $6.8 million in Q1 2021.
• The 5-year median for Other Non-Current Liabilities is $293.1 million (2021), against an average of $336.5 million.
• Across the five-year window, Other Non-Current Liabilities surged 25243.82% in 2021 and slumped 69.22% in 2025, its largest moves.
• BioNTech SE's Other Non-Current Liabilities stood at $211.5 million in 2021, then soared by 77.12% to $374.6 million in 2022, then fell by 22.66% to $289.8 million in 2023, then slumped by 46.6% to $154.7 million in 2024, then advanced by 9.31% to $169.1 million in 2025.
• The last three Other Non-Current Liabilities figures came in at $169.1 million (Q4 2025), $247.3 million (Q3 2025), and $164.8 million (Q2 2025), per Business Quant data.